Drug Name: Rezlidhia

Active Ingredient: olutasidenib

Indications: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

Approval Date: 12/1/2022

Company: Forma Therapeutics, Inc (A Novo Nordisk company)

Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *